Patents by Inventor Lisa C. Kadyk

Lisa C. Kadyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PIK4CA as modifier of the Rac pathway and methods of use
    Patent number: 8481269
    Abstract: Human PIK4CA genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of PIK4CA are provided.
    Type: Grant
    Filed: September 15, 2005
    Date of Patent: July 9, 2013
    Assignee: Exelixis, Inc.
    Inventors: Lisa C. Kadyk, George Ross Francis, Lynn Margaret Bjerke, Timothy S. Heuer
  • MAPKs as modifiers of the rac, axin, and beta-catenin pathways and methods of use
    Patent number: 8067180
    Abstract: Human MAPK genes are identified as modulators of the Rac, axin, and beta-catenin pathways, and thus are therapeutic targets for disorders associated with defective Rac, axin, and beta-catenin function. Methods for identifying modulators of Rac, axin, and beta-catenin, comprising screening for agents that modulate the activity of MAPK are provided.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: November 29, 2011
    Assignee: Exelixis, Inc.
    Inventors: Lisa C. Kadyk, George Ross Francis, Steven Brian Gendreau, Emery G. Dora, III, Michael R. Costa, Kim Lickteig
  • CSNKS As Modifiers of the RAC Pathway and Methods of Use
    Publication number: 20110033853
    Abstract: Human CSNK genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of CSNK are provided.
    Type: Application
    Filed: May 5, 2010
    Publication date: February 10, 2011
    Applicant: EXELIXIS, INC.
    Inventors: LISA C. KADYK, GEORGE ROSS FRANCIS, LYNN MARGARET BJERKE
  • Pik4ca As Modifier of the Rac Pathway and Methods of Use
    Publication number: 20080263684
    Abstract: Human PIK4CA genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of PIK4CA are provided.
    Type: Application
    Filed: September 15, 2005
    Publication date: October 23, 2008
    Applicant: EXELIXIS INC.
    Inventors: Lisa C. Kadyk, George Ross Francis, Lynn Margaret Bjerke, Timothy S. Heuer
  • Mapks as Modifiers of the Rac, Axin, and Beta-Catenin Pathways and Methods of Use
    Publication number: 20080229435
    Abstract: Human MAPK genes are identified as modulators of the Rac, axin, and beta-catenin pathways, and thus are therapeutic targets for disorders associated with defective Rac, axin, and beta-catenin function. Methods for identifying modulators of Rac, axin, and beta-catenin, comprising screening for agents that modulate the activity of MAPK are provided.
    Type: Application
    Filed: November 24, 2003
    Publication date: September 18, 2008
    Applicant: EX-ELIXIS, INC
    Inventors: Lisa C. Kadyk, George Ross Francis, Steven Brian Gendreau, Emery G. Dora, Michael R. Costa, Kim Lickteig
  • Srebp pathway modulation through targeting hisrs
    Publication number: 20040101879
    Abstract: Human HisRS genes are identified as modulators of the SREPB pathway and thus are therapeutic for disorders associated with the SREBP pathway. Methods for identifying modulators of HisRS, comprising screening for agents that modulate the activity of HisRS are provided.
    Type: Application
    Filed: November 4, 2003
    Publication date: May 27, 2004
    Inventors: Cynthia Seidel-Dugan, Lisa C. Kadyk, Felipa A. Mapa
  • Modulating insulin receptor signaling through targeting FACL
    Publication number: 20030138832
    Abstract: Human FACL genes are identified as modulators of INR signaling and thus are therapeutic targets for disorders associated with defective INR signaling. Methods for identifying modulators of FACL, comprising screening for agents that modulate the activity of FACL are provided.
    Type: Application
    Filed: December 18, 2002
    Publication date: July 24, 2003
    Inventors: Lisa C. Kadyk, Carol L. O'Brien